Ovarian cancer represents the fifth most significant cause of cancer-related death for women and the most frequent cause of death from gynaecological neoplasia in the Western world. The incidence of ovarian cancer in the UK is over 5000 new cases every year, accounting for 4275 deaths per year (Chang et al., 1994) . A recent meta-analysis of all randomised trials of patients with epithelial ovarian cancer after surgery demonstrated an overall 5 year survival of 30% (Advanced Ovarian Cancer Trialists Group, 1991) . Five year survival rates are as follows: stage I, 70%; stage II, 45%; stage III, 17%; and stage IV, 5% (Chang et al., 1994) . The high overall mortality is due to the majority of patients presenting with stage III and IV disease. Clearly, any methods that enable the early detection of ovarian cancer would lead to a significant decrease in mortality.
Ovarian cancer encompasses a broad spectrum of lesions, ranging from localised benign tumours and tumours of borderline malignant potential, through to invasive malignant adenocarcinomas. Histologically, the common epithelial ovarian cancers, which account for 90% of all ovarian cancer, are classified into several types, that is serous, mucinous, endometrioid, clear cell, Brenner, mixed epithelial and undifferentiated tumours. The different histological subtypes reflect the considerable differentiation potential of the ovarian surface epithelium.
The aetiology of ovarian cancer is not completely understood, although both epidemiological and genetic associations have been recorded. Epidemiological factors related to ovulation seem to be important (Fathalla, 1971) , whereby ovarian epithelial cells undergo several rounds of division and proliferative growth to heal the wound in the epithelial surface, thereby increasing the chance of a genetic accident during the repair process, such as the activation of an oncogene or the inactivation of a tumour-suppressor gene (Berek et al., 1993) . The genetic changes occurring in epithelial ovarian cancer are also poorly understood and, except for the analysis of the p53 gene, the majority have not yet been defined. This review focuses on the current understanding of cytogenetic abnormalities, linkage and allele loss studies that signpost chromosomal regions which may contain relevant genes. The emphasis of this review is on recessively acting rather than dominant genes (reviewed recently in Berchuck et al., 1992) as the isolation of tumoursuppressor genes will lay the foundation for an improved understanding of the mechanisms involved in tumorigenesis.
Clonality
At surgery, tumours are frequently found in both ovaries and at other locations in the abdomen and pelvis, raising the possibility of a multifocal origin. However, it appears that, like most other neoplasms, ovarian cancer is clonal in origin (Bello and Rey, 1990; Boltz et al., 1990; Pejovic et al., 1991; Jacobs et al., 1992; Mok et al., 1992; Tsao et al., 1993 Tsao et al., 1993) have shown that patterns of allelic deletion and chromosome methylation were identical in both the primary lesion and associated metastatic tumour within a given patient, thus providing support for the unifocal origin of ovarian tumours.
The genetic model for multistep tumour progression of colorectal tumours (Fearon and Vogelstein, 1990) Atkin and Baker. 1987 : Jenkyn and McCartney. 1987 : Sheer et al.. 1987 : Smith et al.. 1987 Pejovic et al.. 1989 Pejovic et al.. . 1990 Pejovic et al.. . 1991 Pejovic et al.. . 1992 Tanaka et al.. 1989 : Bello and Rey. 1990 : Roberts and Tattersall. 1990 : Islam et al.. 1993 : Thompson et al.. 1994 . The cytogenetic data have allowed investigators to evaluate the role of some of these chromosomal alterations using more sensitive and precise methods. that is using highly polymorphic markers for linkage analysis of familial cancer and loss of heterozygosity studies in sporadic tumours.
Linkage
The majority of ovarian cancers are sporadic. but a predisposition to tumour development can be inherited as an autosomal dominant trait. Female members of ovarian cancer families may have a lifetime risk for ovarian cancer 2-or 3-fold greater than the general female population. and are often found clustered with stomach. breast and colon cancer (Blackett and Sharp. 1994 Eccles et al. (1990 Eccles et al. ( . 1992b . Lee et al. (1990) . Okamoto et al. (1991) . Sato et al. (1991) . Tsao et al. (1993) . Viel et al. (1991 Viel et al. ( . 1992 . Zheng et al. (1991. 1993) . CheneVix-Trench et al. (1992 . Gallion et al. (1992) . Jacobs et al. (1992. 1993 ). Jones and Nakamura (1992) . Allelic losses of up to 50% involving 6q have been frequently reported (38%. Table I ). Several studies have shown by either loss of heterozygosity (Sato et al.. 1991 Saito et al.. 1993 or cytogenetic abnormalities (Wake et al., 1980) . that these changes occur more frequently in serous adenocarcinomas, implying that 6q may be important in the pathogenesis of the more common serous adenocarcinomas (Sato et al.. 1991 (Laird and Jaenisch. 1994 .
Conclusion
The positional cloning of putatix-e tumour-suppressor genes identified from allele loss studies *-ill lay the foundation for a better understanding of the pathogenesis of ox-arian cancer. The identification of BRC41 and BRC.4' u-ould be of direct clinical benefit to probands in breast-oarian cancer families. The isolation and characterisation of oncogenes and tumour-suppressor genes has sexveral clinical applications. First. persons at high risk of oxarian cancer (such as oxarian cancer families ) can be screened by molecular approaches and offered prophylactic oophorectomy if they carry the defectixe gene. Second. it is also conceixable that such genes or their products may be the basis of a general screening approach for ox-arian cancer. Diaanosis could be made relatixely simply by the identification of mutant gene products in the blood. or by the detection of antibodies made by the patient against the mutant gene product. Third. neu-er therapeutic approaches designed to inactix ate mutant gene products (e.g. c-erbB-2' or mimic or restore the normal biological function of genes like p53 will be possible. Finally.
gene therapy x-ould be an appealingz xvay to restore function in patients x-ho hax-e oxarian cancer once it is possible to 
